CARDIFF ONCOLOGY INC (CRDF)
US14147L1089 - Common Stock
ChartMill assigns a Buy % Consensus number of 84% to CRDF. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 9.52. This target is 114.17% above the current price.
CRDF was analyzed by 11 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about CRDF.
In the previous month the buy percentage consensus was at a similar level.
CRDF was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-12-13 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-11-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-09-06 | Craig-Hallum | Initiate | Buy |
| 2024-05-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-01 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-08-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-05-09 | HC Wainwright & Co. | Maintains | Buy |
| 2023-03-29 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-07 | HC Wainwright & Co. | Maintains | Buy |
| 2022-09-16 | HC Wainwright & Co. | Maintains | Buy |
| 2022-09-13 | Piper Sandler | Maintains | Overweight |
| 2022-08-29 | Baird | Maintains | Outperform |
| 2022-05-09 | HC Wainwright & Co. | Maintains | Buy |
| 2022-02-28 | HC Wainwright & Co. | Maintains | Buy |
| 2021-12-08 | Baird | Initiate | Outperform |
| 2021-08-10 | HC Wainwright & Co. | Maintains | Buy |
| 2021-05-10 | HC Wainwright & Co. | Maintains | Buy |